Business
Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures - Demonstrated a significant improvement with 6-minute walk
About this update from Tenax Therapeutics, Inc.
[{"type":"text","content":"\n - Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures \n\n\n- Demonstrated a significant improvement with 6-minute walk distance\n\n\n- No significant safety issues.\n\n\n- Management to host conference call and webcast today at 8:30 a.m. EDT\n\n MORRISVILLE, N.C.--(BUSINESS WIRE)--\nTenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced positive Phase 2 results for levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). In this 37 patient study, the primary efficacy analysis, pulmonary capillary wedge pressure (PCWP) during exercise did not demonstrate a statistically significant reduction from baseline. Levosimendan did demonstrate a statistically significant reduction in PCWP compared to baseline (p=","length":1443,"tagName":"div"}]